Journal of Antimicrobial Chemotherapy, Vol 41, 41-46, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy
MR Haeney
Complement provides a critical and multifaceted defence system against
infection. Following activation, complement can clear invading
microorganisms by lysis or by opsonization, which promotes recognition by
complement receptors on phagocytes. Complement activation products promote
a local inflammatory response and are involved in the modulation of
adaptive immune responses that lead to antibody production. The host has
developed regulatory mechanisms for controlling complement activation and
for protecting its own cells against complement attack. Some microorganisms
have also evolved ways to avoid the opsonic and lytic action of complement.
ORIGINAL ARTICLES
The role of the complement cascade in sepsis
Department of Immunology, Salford Royal Hospitals NHS Trust, Hope Hospital, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. P. Rivers, L. McIntyre, D. C. Morro, and K. K. Rivers Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity Can. Med. Assoc. J., October 25, 2005; 173(9): 1054 - 1065. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Freeman, S. D. Baines, D. Jabes, and M. H. Wilcox Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection J. Antimicrob. Chemother., October 1, 2005; 56(4): 717 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Poutanen and A. E. Simor Treating C. difficile Can. Med. Assoc. J., February 15, 2005; 172(4): 448 - 448. [Full Text] [PDF]
|
|
|
|
|
|
M. Wullt and I. Odenholt A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea J. Antimicrob. Chemother., July 1, 2004; 54(1): 211 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Dridi, J. Tankovic, B. Burghoffer, F. Barbut, and J.-C. Petit gyrA and gyrB Mutations Are Implicated in Cross-Resistance to Ciprofloxacin and Moxifloxacin in Clostridium difficile Antimicrob. Agents Chemother., November 1, 2002; 46(11): 3418 - 3421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Farrow, D. Lyras, and J. I. Rood Genomic analysis of the erythromycin resistance element Tn5398 from Clostridium difficile Microbiology, October 1, 2001; 147(10): 2717 - 2728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Modi and M H Wilcox Evidence for antibiotic induced Clostridium perfringens diarrhoea J. Clin. Pathol., October 1, 2001; 54(10): 748 - 751. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Keller and E. R. Stiehm Passive Immunity in Prevention and Treatment of Infectious Diseases Clin. Microbiol. Rev., October 1, 2000; 13(4): 602 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Barbut, A. Richard, K. Hamadi, V. Chomette, B. Burghoffer, and J.-C. Petit Epidemiology of Recurrences or Reinfections of Clostridium difficile-Associated Diarrhea J. Clin. Microbiol., June 1, 2000; 38(6): 2386 - 2388. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Stubbe, J. Berdoz, J.-P. Kraehenbuhl, and B. Corthesy Polymeric IgA Is Superior to Monomeric IgA and IgG Carrying the Same Variable Domain in Preventing Clostridium difficile Toxin A Damaging of T84 Monolayers J. Immunol., February 15, 2000; 164(4): 1952 - 1960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Ward, G. Douce, G. Dougan, and B. W. Wren Local and Systemic Neutralizing Antibody Responses Induced by Intranasal Immunization with the Nontoxic Binding Domain of Toxin A from Clostridium difficile Infect. Immun., October 1, 1999; 67(10): 5124 - 5132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Samuelson Why Metronidazole Is Active against both Bacteria and Parasites Antimicrob. Agents Chemother., July 1, 1999; 43(7): 1533 - 1541. [Full Text]
|
|